Phase II A Trial of Curcumin Among Patients With Prevalent Subclinical Neoplastic Lesions (Aberrant Crypt Foci)

NCT00365209 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

44

Enrollment

NIH

Sponsor class

Conditions

Healthy, no Evidence of Disease
Tobacco Use Disorder

Interventions

OTHER: laboratory biomarker analysis
OTHER: pharmacological study
DRUG: curcumin

Sponsor

National Cancer Institute (NCI)